Recent Advances in Endometrial Cancer [version 1; referees: 2 approved]
Endometrial cancer is the most common gynecologic malignancy in the United States, with yearly rates continuing to increase. Most women present with early stage disease; however, advanced disease carries a grave prognosis. As a result, novel therapies are currently under investigation for the treatm...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
F1000 Research Ltd
2017-01-01
|
Series: | F1000Research |
Subjects: | |
Online Access: | https://f1000research.com/articles/6-81/v1 |
id |
doaj-0df450ce446344cda7134aae28ce2640 |
---|---|
record_format |
Article |
spelling |
doaj-0df450ce446344cda7134aae28ce26402020-11-25T03:02:46ZengF1000 Research LtdF1000Research2046-14022017-01-01610.12688/f1000research.10020.110796Recent Advances in Endometrial Cancer [version 1; referees: 2 approved]Arthur-Quan Tran0Paola Gehrig1Gynecologic Oncology, University of North Carolina at Chapel Hill, NC, USAGynecologic Oncology, University of North Carolina at Chapel Hill, NC, USAEndometrial cancer is the most common gynecologic malignancy in the United States, with yearly rates continuing to increase. Most women present with early stage disease; however, advanced disease carries a grave prognosis. As a result, novel therapies are currently under investigation for the treatment of endometrial cancer. These advances include a better understanding of the genetic basis surrounding the development of endometrial cancer, novel surgical therapies, and new molecular targets for the treatment of this disease. This review explores the literature regarding these advancements in endometrial cancer.https://f1000research.com/articles/6-81/v1Cancer TherapeuticsGynecological CancersImmunopharmacology & Hematologic PharmacologyMedical GeneticsPharmacogenomics |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Arthur-Quan Tran Paola Gehrig |
spellingShingle |
Arthur-Quan Tran Paola Gehrig Recent Advances in Endometrial Cancer [version 1; referees: 2 approved] F1000Research Cancer Therapeutics Gynecological Cancers Immunopharmacology & Hematologic Pharmacology Medical Genetics Pharmacogenomics |
author_facet |
Arthur-Quan Tran Paola Gehrig |
author_sort |
Arthur-Quan Tran |
title |
Recent Advances in Endometrial Cancer [version 1; referees: 2 approved] |
title_short |
Recent Advances in Endometrial Cancer [version 1; referees: 2 approved] |
title_full |
Recent Advances in Endometrial Cancer [version 1; referees: 2 approved] |
title_fullStr |
Recent Advances in Endometrial Cancer [version 1; referees: 2 approved] |
title_full_unstemmed |
Recent Advances in Endometrial Cancer [version 1; referees: 2 approved] |
title_sort |
recent advances in endometrial cancer [version 1; referees: 2 approved] |
publisher |
F1000 Research Ltd |
series |
F1000Research |
issn |
2046-1402 |
publishDate |
2017-01-01 |
description |
Endometrial cancer is the most common gynecologic malignancy in the United States, with yearly rates continuing to increase. Most women present with early stage disease; however, advanced disease carries a grave prognosis. As a result, novel therapies are currently under investigation for the treatment of endometrial cancer. These advances include a better understanding of the genetic basis surrounding the development of endometrial cancer, novel surgical therapies, and new molecular targets for the treatment of this disease. This review explores the literature regarding these advancements in endometrial cancer. |
topic |
Cancer Therapeutics Gynecological Cancers Immunopharmacology & Hematologic Pharmacology Medical Genetics Pharmacogenomics |
url |
https://f1000research.com/articles/6-81/v1 |
work_keys_str_mv |
AT arthurquantran recentadvancesinendometrialcancerversion1referees2approved AT paolagehrig recentadvancesinendometrialcancerversion1referees2approved |
_version_ |
1724688499606552576 |